<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43390">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01681225</url>
  </required_header>
  <id_info>
    <org_study_id>2011P-000242</org_study_id>
    <nct_id>NCT01681225</nct_id>
  </id_info>
  <brief_title>EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures</brief_title>
  <acronym>EPVent2</acronym>
  <official_title>EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures (EPVent2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II multi-centered, randomized controlled trial of mechanical ventilation directed
      by esophageal pressure measurement will test the primary hypothesis that using a strategy of
      maintaining a minimal but positive transpulmonary pressure (PTP = airway pressure minus
      pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient
      survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A composite outcome of mortality and time off the ventilator at 28-days.</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>The trial will utilize a primary composite endpoint that incorporates death and days off the ventilator at 28 days in such a manner that death constitutes a more serious outcome.  Every subject in the treatment group is compared to every subject in the control group and assigned one number resulting from each comparison. Since mortality outcome is clinically more important, mortality takes precedence over days off the ventilator.  These scores are summed up to obtain a cumulative score for each subject.  The cumulative scores are added up for each treatment group to form a test statistic by the Mann-Whitney technique.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days to day 28</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>Day 60</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hospital and ICU mortality to days 28 and 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lengths of stay</measure>
    <time_frame>Day 60</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hospital and ICU lengths of stay to days 28 and 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarkers of lung injury</measure>
    <time_frame>Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma biomarkers of lung injury on enrollment and days 3 and 7 after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will assess via questionnaires (SF-12, Barthel Index, VES-13) done by phone at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue therapy</measure>
    <time_frame>Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Rescue measures will be chosen according to the practice at the clinical site, and may include repeated recruitment maneuvers, prone positioning, nitric oxide, epoprostenol sodium, airway pressure release ventilation, high frequency ventilation, or ECMO.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>EPVent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The overall goals for the &quot;EPVent&quot; group (esophageal-pressure guided mechanical ventilation) are to employ an open-lung strategy that includes low tidal volumes and maintenance of a positive transpulmonary pressure at end-expiration [Ptpexp].  Fraction of inspired oxygen [FiO2] and transpulmonary pressure pressure during an expiratory hold will be changed to achieve values shown in one of the columns of a protocol-specified table to meet the oxygenation target.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The overall goals for the Control group are similar to those for the EPVent group: to employ an open-lung strategy that includes low tidal volumes using an alternative high positive end-expiratory pressure [PEEP] strategy. The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements. PEEP and FiO2 will be raised or lowered to achieve the oxygenation target level</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Esophageal-pressure guided mechanical ventilation</intervention_name>
    <arm_group_label>EPVent</arm_group_label>
    <other_name>mechanical ventilation strategy</other_name>
    <other_name>open-lung strategy</other_name>
    <other_name>EPVent</other_name>
    <other_name>positive transpulmonary pressure at end-expiration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High PEEP mechanical ventilation</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute onset of ARDS as defined by the Berlin Consensus Conference definitions:

               1. Hypoxemic respiratory failure with PaO2 / FIO2 ratio &lt; 200 mmHg

               2. b) Bilateral alveolar/interstitial infiltrates on chest x-ray, with opacities
                  not present for more than 7 days

               3. Respiratory failure not fully explained by cardiac failure or fluid overload

               4. Intubation on controlled ventilation and receiving PEEP ≥ 5 cm H2O

          -  Age 16 years or older

          -  Duration of ARDS 36 hours or less from meeting final Berlin criterion.

        Exclusion Criteria:

          -  Received mechanical ventilation more than 96 hours

          -  Recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal
             trauma, recent esophageal surgery or other contraindication for nasogastric tube
             placement

          -  Severe coagulopathy (platelet count &lt; 5000/microliter or INR &gt; 3)

          -  History of lung or liver transplantation

          -  Elevated intracranial pressure or conditions where hypercapnia-induced elevations in
             intracranial pressure should be avoided

          -  Evidence of active air leak from the lung

          -  not committed to full support

          -  Participation in other intervention trials for ARDS or for sepsis within the past 30
             days.

          -  Neuromuscular disease that impairs ability to ventilate spontaneously

          -  Severe chronic liver disease, defined as Child-Pugh Score of ≥12

          -  Treating clinician refusal, or unwillingness to commit to controlled ventilation for
             at least 24 hours

          -  Inability to get informed consent from the patient or surrogate.

          -  Use of rescue therapies for prior to enrollment (e.g. nitric oxide, ECMO, prone
             positioning, high frequency oscillation). This does not exclude cases where these
             therapies were used as the initial mode of ventilation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel s Talmor, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel S Talmor, MD MPH</last_name>
    <phone>617-754-2675</phone>
    <email>dtalmor@bidmc.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie M Banner-Goodspeed, ALB</last_name>
    <phone>617-754-2675</phone>
    <email>vgoodspe@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Edgar Jimenez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert S Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Atul Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Owens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Sarge, MD</last_name>
      <phone>617-667-3112</phone>
      <email>tsarge@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Sarge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusets Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephen Heard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michelle Gong, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Donald Griesdale, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med. 2005 Oct 20;353(16):1685-93.</citation>
    <PMID>16236739</PMID>
  </reference>
  <reference>
    <citation>Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, Stewart TE, Barr A, Cook D, Slutsky AS; Canadian Critical Care Trials Group. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003 Feb 20;348(8):683-93.</citation>
    <PMID>12594312</PMID>
  </reference>
  <reference>
    <citation>Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, Slutsky AS, Pullenayegum E, Zhou Q, Cook D, Brochard L, Richard JC, Lamontagne F, Bhatnagar N, Stewart TE, Guyatt G. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010 Mar 3;303(9):865-73. doi: 10.1001/jama.2010.218. Review.</citation>
    <PMID>20197533</PMID>
  </reference>
  <reference>
    <citation>Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, Schoenfeld D, Thompson BT; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004 Jul 22;351(4):327-36.</citation>
    <PMID>15269312</PMID>
  </reference>
  <reference>
    <citation>Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J, Skrobik Y, Ronco JJ, Stewart TE; Lung Open Ventilation Study Investigators. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008 Feb 13;299(6):637-45.</citation>
    <PMID>18270352</PMID>
  </reference>
  <reference>
    <citation>Gattinoni L, Caironi P, Carlesso E. How to ventilate patients with acute lung injury and acute respiratory distress syndrome. Curr Opin Crit Care. 2005 Feb;11(1):69-76. Review.</citation>
    <PMID>15659948</PMID>
  </reference>
  <reference>
    <citation>Talmor D, Sarge T, Malhotra A, O'Donnell CR, Ritz R, Lisbon A, Novack V, Loring SH. Mechanical ventilation guided by esophageal pressure in acute lung injury. N Engl J Med. 2008 Nov 13;359(20):2095-104. Epub 2008 Nov 11.</citation>
    <PMID>19001507</PMID>
  </reference>
  <reference>
    <citation>Talmor D, Sarge T, O'Donnell CR, Ritz R, Malhotra A, Lisbon A, Loring SH. Esophageal and transpulmonary pressures in acute respiratory failure. Crit Care Med. 2006 May;34(5):1389-94.</citation>
    <PMID>16540960</PMID>
  </reference>
  <reference>
    <citation>Sarge T, Talmor D. Targeting transpulmonary pressure to prevent ventilator induced lung injury. Minerva Anestesiol. 2009 May;75(5):293-9. Review.</citation>
    <PMID>19412147</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 22, 2012</lastchanged_date>
  <firstreceived_date>September 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>ALI</keyword>
  <keyword>esophageal pressure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
